Skip to content

Clinical trials

Observational Wounds and Injuries trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Wounds and Injuries Phase: Observational Country / region: China Clear all

20 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20021
20101
20121
20131
20141
20151
20171
20203
20212
20222
20233
20241
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed9
Unknown status8
Recruiting2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Second Affiliated Hospital, Zhejiang University, School of Medicine4
Nanjing PLA General Hospital2
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine2
BioChain (Beijing) Science and Technology, Inc.1
First Affiliated Hospital Xi'an Jiaotong University1
General Hospital of Ningxia Medical University1
Guangzhou General Hospital of Guangzhou Military Command1
Jiang Jianxin1
Jinling Hospital, China1
Nanfang Hospital, Southern Medical University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Wounds and Injuries20
Multiple Organ Failure2
Adenoma1
Arthritis1
Brain Injuries1
Brain Injuries, Traumatic1
Cardiovascular Diseases1
Cerebral Hemorrhage1
Cerebral Small Vessel Diseases1
Colorectal Neoplasms1

Trials

Showing 1 to 20 of 20. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.